BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38321459)

  • 1. Assessing availability, prices, and market share of quality-assured malaria ACT and RDT in the private retail sector in Nigeria and Uganda.
    Woldeghebriel M; Aso E; Berlin E; Fashanu C; Kirumira SN; Lam F; Mugerwa R; Nakiganda J; Olaleye T; Opigo J; Osinupebi F; Priestley N; Stringham R; Uhomoibhi P; Visser T; Ward A; Wiwa O; Woolsey A
    Malar J; 2024 Feb; 23(1):41. PubMed ID: 38321459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subsidising artemisinin-based combination therapy in the private retail sector.
    Opiyo N; Yamey G; Garner P
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009926. PubMed ID: 26954551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries.
    O'Connell KA; Gatakaa H; Poyer S; Njogu J; Evance I; Munroe E; Solomon T; Goodman C; Hanson K; Zinsou C; Akulayi L; Raharinjatovo J; Arogundade E; Buyungo P; Mpasela F; Adjibabi CB; Agbango JA; Ramarosandratana BF; Coker B; Rubahika D; Hamainza B; Chapman S; Shewchuk T; Chavasse D
    Malar J; 2011 Oct; 10():326. PubMed ID: 22039838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What happened to anti-malarial markets after the Affordable Medicines Facility-malaria pilot? Trends in ACT availability, price and market share from five African countries under continuation of the private sector co-payment mechanism.
    ; Tougher S; Hanson K; Goodman C
    Malar J; 2017 Apr; 16(1):173. PubMed ID: 28441956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing times: trends in availability, price, and market share of malaria diagnostics in the public and private healthcare sector across eight sub-Saharan African countries from 2009 to 2015.
    ; Hanson K; Goodman C
    Malar J; 2017 May; 16(1):205. PubMed ID: 28526075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copayment mechanism in selected districts of Uganda: Availability, market share and price of quality assured artemisinin-based combination therapies in private drug outlets.
    Ocan M; Nambatya W; Otike C; Nakalembe L; Nsobya S
    PLoS One; 2024; 19(3):e0295198. PubMed ID: 38536824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the Affordable Medicines Facility--malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data.
    Tougher S; ; Ye Y; Amuasi JH; Kourgueni IA; Thomson R; Goodman C; Mann AG; Ren R; Willey BA; Adegoke CA; Amin A; Ansong D; Bruxvoort K; Diallo DA; Diap G; Festo C; Johanes B; Juma E; Kalolella A; Malam O; Mberu B; Ndiaye S; Nguah SB; Seydou M; Taylor M; Rueda ST; Wamukoya M; Arnold F; Hanson K
    Lancet; 2012 Dec; 380(9857):1916-26. PubMed ID: 23122217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment-seeking patterns for malaria in pharmacies in five sub-Saharan African countries.
    Ladner J; Davis B; Audureau E; Saba J
    Malar J; 2017 Aug; 16(1):353. PubMed ID: 28851358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cross-sectional study of the availability and price of anti-malarial medicines and malaria rapid diagnostic tests in private sector retail drug outlets in rural Western Kenya, 2013.
    Kioko U; Riley C; Dellicour S; Were V; Ouma P; Gutman J; Kariuki S; Omar A; Desai M; Buff AM
    Malar J; 2016 Jul; 15(1):359. PubMed ID: 27406179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The malaria testing and treatment landscape in mainland Tanzania, 2016.
    ; Michael D; Mkunde SP
    Malar J; 2017 Apr; 16(1):202. PubMed ID: 28521811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The malaria testing and treatment market in Kinshasa, Democratic Republic of the Congo, 2013.
    ; Mpanya G; Tshefu A; Likwela JL
    Malar J; 2017 Feb; 16(1):94. PubMed ID: 28241832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in access to anti-malarial treatment in the formal private sector in Uganda: an assessment of availability and affordability of first-line anti-malarials and diagnostics between 2007 and 2018.
    Kibira D; Ssebagereka A; van den Ham HA; Opigo J; Katamba H; Seru M; Reed T; Leufkens HG; Mantel-Teeuwisse AK
    Malar J; 2021 Mar; 20(1):142. PubMed ID: 33691704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving rational use of ACTs through diagnosis-dependent subsidies: Evidence from a cluster-randomized controlled trial in western Kenya.
    Prudhomme O'Meara W; Menya D; Laktabai J; Platt A; Saran I; Maffioli E; Kipkoech J; Mohanan M; Turner EL
    PLoS Med; 2018 Jul; 15(7):e1002607. PubMed ID: 30016316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanding access to parasite-based malaria diagnosis through retail drug shops in Tanzania: evidence from a randomized trial and implications for treatment.
    Maloney K; Ward A; Krenz B; Petty N; Bryson L; Dolkart C; Visser T; Le Menach A; Scott VK; Cohen JM; Mtumbuka E; Mkude S
    Malar J; 2017 Jan; 16(1):6. PubMed ID: 28049481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the availability and affordability of subsidised artemisinin combination therapy in the private drug retail sector in rural Ghana: before and after the introduction of the AMFm subsidy.
    Ansah EK; Whitty CJ; Bart-Plange C; Gyapong M
    Int Health; 2016 Nov; 8(6):427-432. PubMed ID: 27744327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Artemisinin-based combination therapy availability and use in the private sector of five AMFm phase 1 countries.
    Davis B; Ladner J; Sams K; Tekinturhan E; de Korte D; Saba J
    Malar J; 2013 Apr; 12():135. PubMed ID: 23607504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prices and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-endemic countries.
    Palafox B; Patouillard E; Tougher S; Goodman C; Hanson K; Kleinschmidt I; Torres Rueda S; Kiefer S; O'Connell K; Zinsou C; Phok S; Akulayi L; Arogundade E; Buyungo P; Mpasela F; Poyer S; Chavasse D
    Health Policy Plan; 2016 Mar; 31(2):148-60. PubMed ID: 25944705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of the private sector co-payment mechanism (PSCM) on the private market for ACT in Nigeria: results of the 2018 cross-sectional outlet and household market surveys.
    Edwards HM; Sarwar R; Mahmud P; Emmanuel S; Maxwell K; Tibenderana JK
    Malar J; 2022 Feb; 21(1):42. PubMed ID: 35151332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The private sector market for malaria rapid diagnostic tests in Nigeria: results of the 2018 market survey.
    Edwards HM; Sarwar R; Mahmud P; Emmanuel S; Maxwell K; Tibenderana JK
    Malar J; 2022 Jun; 21(1):190. PubMed ID: 35710474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study.
    Talisuna AO; Daumerie PG; Balyeku A; Egan T; Piot B; Coghlan R; Lugand M; Bwire G; Rwakimari JB; Ndyomugyenyi R; Kato F; Byangire M; Kagwa P; Sebisubi F; Nahamya D; Bonabana A; Mpanga-Mukasa S; Buyungo P; Lukwago J; Batte A; Nakanwagi G; Tibenderana J; Nayer K; Reddy K; Dokwal N; Rugumambaju S; Kidde S; Banerji J; Jagoe G
    Malar J; 2012 Oct; 11():356. PubMed ID: 23107021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.